These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 37298274)

  • 1. An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus.
    Mahgoub MO; Ali II; Adeghate JO; Tekes K; Kalász H; Adeghate EA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management.
    Goodarzi MO; Petrov MS
    Drugs; 2023 Aug; 83(12):1077-1090. PubMed ID: 37410209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
    Munir KM; Davis SN
    Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
    Tahrani AA; Barnett AH; Bailey CJ
    Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of diabetes: therapies for type 2 diabetes.
    Tsoutsouki J; Wunna W; Chowdhury A; Chowdhury TA
    Postgrad Med J; 2020 Oct; 96(1140):610-618. PubMed ID: 32467106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body Weight Considerations in the Management of Type 2 Diabetes.
    Apovian CM; Okemah J; O'Neil PM
    Adv Ther; 2019 Jan; 36(1):44-58. PubMed ID: 30465123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of type 2 diabetes mellitus: an update.
    El-Kaissi S; Sherbeeni S
    Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas.
    Brooks LK; Kalyanaraman N; Malek R
    Am J Med; 2019 Apr; 132(4):408-412. PubMed ID: 30472322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
    Hahr AJ; Molitch ME
    Am J Kidney Dis; 2022 May; 79(5):728-736. PubMed ID: 34600745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.
    Iacobellis G; Basilico S; Malavazos AE
    Handb Exp Pharmacol; 2022; 274():93-108. PubMed ID: 35156138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
    Braunstein S
    Clin Ther; 2003 Jul; 25(7):1895-917. PubMed ID: 12946541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.